Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$15.25
$15.23
$4.81
$15.37
$753.61M-0.06974,748 shs600 shs
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
$10.23
-16.0%
$0.00
$8.29
$14.26
$327.16M-0.46358,732 shs133,262 shs
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$0.70
+22.0%
$0.47
$0.27
$1.08
$32.04M0.122.14 million shs4.87 million shs
Bio-Techne Co. stock logo
TECH
Bio-Techne
$48.31
-3.1%
$50.02
$46.01
$83.62
$7.57B1.461.37 million shs2.21 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
+21.80%+135.14%+407.50%+90.31%-33.04%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
+22.04%+21.91%+48.94%+78.66%-32.04%
Bio-Techne Co. stock logo
TECH
Bio-Techne
-3.09%-0.04%+1.24%-24.95%-39.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
N/AN/AN/AN/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
2.3169 of 5 stars
3.55.00.00.00.00.01.3
Bio-Techne Co. stock logo
TECH
Bio-Techne
4.9182 of 5 stars
4.23.01.74.23.81.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
0.00
N/AN/AN/A
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
0.00
N/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
3.00
Buy$4.00471.43% Upside
Bio-Techne Co. stock logo
TECH
Bio-Techne
2.45
Hold$72.0049.04% Upside

Current Analyst Ratings Breakdown

Latest TECH, AERI, IPA, and DDC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/30/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$59.00
5/9/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $70.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$72.00 ➝ $63.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$75.00 ➝ $60.00
5/8/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $75.00
4/11/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/9/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Sector Weight
4/1/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00
3/31/2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $5.00
3/18/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
$194.13M3.88N/AN/A($3.32) per share-4.59
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
$28.94M11.30N/AN/A$0.45 per share22.73
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
$24.00M1.33N/AN/A$0.93 per share0.75
Bio-Techne Co. stock logo
TECH
Bio-Techne
$1.21B6.27$1.71 per share28.30$13.15 per share3.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
-$74.81M-$0.77N/AN/AN/A-17.09%N/A-2.00%N/A
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
-$23.43MN/A0.00N/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$20.13M-$1.16N/AN/AN/A-114.50%-73.74%-42.68%7/3/2025 (Estimated)
Bio-Techne Co. stock logo
TECH
Bio-Techne
$168.10M$0.8248.8024.522.8813.22%12.73%9.75%8/6/2025 (Estimated)

Latest TECH, AERI, IPA, and DDC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q3 2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
3/28/2025Q3 2025
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
-$0.06-$0.06N/A-$0.46$6.59 million$4.23 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/AN/AN/AN/AN/A
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
N/AN/AN/AN/AN/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
N/AN/AN/AN/AN/A
Bio-Techne Co. stock logo
TECH
Bio-Techne
$0.320.66%N/A39.02%N/A

Latest TECH, AERI, IPA, and DDC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/19/2025
Bio-Techne Co. stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
N/A
2.27
1.92
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
0.04
0.94
0.92
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
0.36
1.01
0.85
Bio-Techne Co. stock logo
TECH
Bio-Techne
0.14
3.94
2.77

Institutional Ownership

CompanyInstitutional Ownership
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
95.94%
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
0.22%
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.70%
Bio-Techne Co. stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
4.44%
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
N/A
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
6.83%
Bio-Techne Co. stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aerie Pharmaceuticals, Inc. stock logo
AERI
Aerie Pharmaceuticals
37649.42 million47.22 millionOptionable
Dominion Diamond Co. stock logo
DDC
Dominion Diamond
N/A31.98 millionN/ANot Optionable
ImmunoPrecise Antibodies Ltd. stock logo
IPA
ImmunoPrecise Antibodies
8045.77 million28.94 millionNot Optionable
Bio-Techne Co. stock logo
TECH
Bio-Techne
3,000156.77 million151.92 millionOptionable

Recent News About These Companies

Bio-Techne (NASDAQ:TECH) Upgraded at Wall Street Zen
Bio-Techne Corporation (TECH): A Bull Case Theory
Bio-Techne to Present at Investor Conferences

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aerie Pharmaceuticals stock logo

Aerie Pharmaceuticals NASDAQ:AERI

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Dominion Diamond stock logo

Dominion Diamond NYSE:DDC

Dominion Diamond Corp is a diamond mining company. The Company is focused on the mining and marketing of rough diamonds to the global market. The Company's segments include the Ekati Diamond Mine, the Diavik Diamond Mine and the Corporate segment. It supplies rough diamonds to the global market from its operation of the Ekati Diamond Mine (in which it owns a controlling interest) and its approximately 40% ownership interest in the Diavik Diamond Mine. It controls the Ekati Diamond Mine, as well as the associated diamond sorting and sales facilities in Toronto and Yellowknife, Canada, Mumbai, India, and Antwerp, Belgium. The Ekati Diamond Mine consists of the Core Zone, which includes the operating mine and other permitted kimberlite pipes, as well as the Buffer Zone, an adjacent area hosting kimberlite pipes having both development and exploration potential, such as the Jay kimberlite pipe and the Lynx kimberlite pipe.

ImmunoPrecise Antibodies stock logo

ImmunoPrecise Antibodies NASDAQ:IPA

$0.70 +0.13 (+22.04%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$0.67 -0.03 (-3.71%)
As of 05:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$48.31 -1.54 (-3.09%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$48.66 +0.35 (+0.73%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.